CA2389173A1 - Agent de traitement de l'hepatite c - Google Patents

Agent de traitement de l'hepatite c Download PDF

Info

Publication number
CA2389173A1
CA2389173A1 CA002389173A CA2389173A CA2389173A1 CA 2389173 A1 CA2389173 A1 CA 2389173A1 CA 002389173 A CA002389173 A CA 002389173A CA 2389173 A CA2389173 A CA 2389173A CA 2389173 A1 CA2389173 A1 CA 2389173A1
Authority
CA
Canada
Prior art keywords
ukrain
patients
ifn
doses
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389173A
Other languages
English (en)
Inventor
Wassyl Nowicky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389173A1 publication Critical patent/CA2389173A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation du produit de conversion des alcaloïdes de Chelidonium majus L. avec de la triaziridide de l'acide thiophosphorique pour produire un médicament destiné au traitement de l'hépatite C.
CA002389173A 2000-03-22 2001-03-20 Agent de traitement de l'hepatite c Abandoned CA2389173A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0048100A AT408719B (de) 2000-03-22 2000-03-22 Mittel zur behandlung von hepatitis c
ATA481/2000 2000-03-22
PCT/AT2001/000076 WO2001070203A2 (fr) 2000-03-22 2001-03-20 Agent de traitement de l'hepatite c

Publications (1)

Publication Number Publication Date
CA2389173A1 true CA2389173A1 (fr) 2001-09-27

Family

ID=3674939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389173A Abandoned CA2389173A1 (fr) 2000-03-22 2001-03-20 Agent de traitement de l'hepatite c

Country Status (17)

Country Link
JP (1) JP2003527414A (fr)
KR (1) KR20020087045A (fr)
CN (1) CN1416347A (fr)
AT (1) AT408719B (fr)
AU (1) AU2001239000A1 (fr)
BG (1) BG107088A (fr)
BR (1) BR0107211A (fr)
CA (1) CA2389173A1 (fr)
EA (1) EA200200584A1 (fr)
HR (1) HRP20020367A2 (fr)
IL (1) IL149314A0 (fr)
IS (1) IS6360A (fr)
MA (1) MA25509A1 (fr)
MX (1) MXPA02004993A (fr)
NO (1) NO20022253L (fr)
PL (1) PL365000A1 (fr)
WO (1) WO2001070203A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695417A5 (de) * 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (fr) 2003-03-18 2004-09-22 Nowicky, Wassyl, Dipl.-Ing. DDr. Dérivés quaternaires de chelidonine et d'alkaloides, procédé pour leur préparation et leur utilisation dans la préparation de médicaments
EP2083825A4 (fr) * 2006-09-26 2009-11-04 Addiction Res Inst Inc Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
CN106343303A (zh) * 2015-07-13 2017-01-25 张如安 灭杀乙肝病毒的饮料
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128018A1 (de) * 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US4816462A (en) * 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer

Also Published As

Publication number Publication date
NO20022253D0 (no) 2002-05-10
KR20020087045A (ko) 2002-11-21
AT408719B (de) 2002-02-25
WO2001070203A2 (fr) 2001-09-27
BG107088A (en) 2003-05-30
PL365000A1 (en) 2004-12-27
CN1416347A (zh) 2003-05-07
HRP20020367A2 (en) 2004-02-29
JP2003527414A (ja) 2003-09-16
WO2001070203A3 (fr) 2002-09-06
BR0107211A (pt) 2004-01-06
NO20022253L (no) 2002-05-10
MXPA02004993A (es) 2003-10-14
IS6360A (is) 2002-04-24
IL149314A0 (en) 2002-11-10
AU2001239000A1 (en) 2001-10-03
ATA4812000A (de) 2001-07-15
EA200200584A1 (ru) 2003-06-26
MA25509A1 (fr) 2002-07-01

Similar Documents

Publication Publication Date Title
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US6007805A (en) Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
KR20010052622A (ko) 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
US20060194835A1 (en) Compositions and methods for treating or preventing flaviviridae infections
JP2005506957A (ja) ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２およびインターフェロンを用いた複合治療
CZ281663B6 (cs) Farmaceutický prostředek pro léčení T-buněčné leukemie (lymfomu dospělých)
US20070015803A1 (en) Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
JP4594734B2 (ja) Ｃ型肝炎、牛ウイルス性下痢症及び豚コレラウイルスを含むフラビウイルス科ウイルスにより生起される感染症の治療のためのエンドペルオキシド類の使用
CZ20011130A3 (cs) Sloučenina, farmaceutický prostředek a jejich použití pro ribavirin-interferon alfa kombinovanou terapii
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
WO2004078193A1 (fr) Therapie medicamenteuse a base d'interferon pour le traitement de maladies virales et de la fibrose hepatique
CA2389173A1 (fr) Agent de traitement de l'hepatite c
WO1994001125A9 (fr) Composition et procede de traitement de l'hepatite b
WO1994001125A1 (fr) Composition et procede de traitement de l'hepatite b
WO2016090107A2 (fr) Traitement d'une infection au virus de l'hépatite delta
WO1994022307A1 (fr) Suppression de l'expression du vih a l'aide de thiophosphate organique
JPS63192718A (ja) 肝障害抑制剤
EP1596883A1 (fr) Therapie de medicament interferon pour le traitement de maladies virales et hepatiques
CA2614639C (fr) Composition pharmaceutique pour le traitement du trouble de la coagulation
CN111632150A (zh) 一种治疗肾病综合征的药物组合物
WO1992004027A1 (fr) Compositions pharmaceutiques destinees au traitement du sida
US20220185823A1 (en) Prevention, Prophylactic and Therapeutic Treatment of Autoimmune Diseases Including Multiple Sclerosis Using Novel Small Molecules and Compositions Thereof
EP0116238A1 (fr) Compositions thérapeutiques et leur application pour améliorer la fonction cérébrale
WO1991004047A1 (fr) Effet synergique de l'interference beta de recombinaison humain sur des pyrimidines halogenees
JPH0867637A (ja) 肝疾患予防治療薬

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040322